SK7732001A3 - Method of treating sexual disturbances - Google Patents

Method of treating sexual disturbances Download PDF

Info

Publication number
SK7732001A3
SK7732001A3 SK773-2001A SK7732001A SK7732001A3 SK 7732001 A3 SK7732001 A3 SK 7732001A3 SK 7732001 A SK7732001 A SK 7732001A SK 7732001 A3 SK7732001 A3 SK 7732001A3
Authority
SK
Slovakia
Prior art keywords
compound according
sexual
medicament
methylamino
dihydro
Prior art date
Application number
SK773-2001A
Other languages
English (en)
Slovak (sk)
Inventor
Martin D Meglasson
Robert B Mccall
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of SK7732001A3 publication Critical patent/SK7732001A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SK773-2001A 1999-01-06 1999-12-20 Method of treating sexual disturbances SK7732001A3 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11484099P 1999-01-06 1999-01-06
US11505199P 1999-01-08 1999-01-08
US11592299P 1999-01-14 1999-01-14
US12054399P 1999-02-17 1999-02-17
PCT/US1999/027951 WO2000040226A2 (en) 1999-01-06 1999-12-20 Method of treating sexual disturbances

Publications (1)

Publication Number Publication Date
SK7732001A3 true SK7732001A3 (en) 2001-12-03

Family

ID=27493976

Family Applications (1)

Application Number Title Priority Date Filing Date
SK773-2001A SK7732001A3 (en) 1999-01-06 1999-12-20 Method of treating sexual disturbances

Country Status (20)

Country Link
US (9) US6455564B1 (hu)
EP (1) EP1140092A2 (hu)
JP (1) JP2002534376A (hu)
KR (1) KR20010089779A (hu)
CN (1) CN1332628A (hu)
AU (1) AU782596B2 (hu)
BR (1) BR9916759A (hu)
CA (1) CA2350946A1 (hu)
CO (1) CO5150156A1 (hu)
CZ (1) CZ20012459A3 (hu)
EA (2) EA200401256A1 (hu)
HK (1) HK1041812A1 (hu)
HU (1) HUP0105036A3 (hu)
ID (1) ID30276A (hu)
IL (1) IL144172A0 (hu)
NZ (1) NZ512820A (hu)
PE (1) PE20001374A1 (hu)
SK (1) SK7732001A3 (hu)
TR (1) TR200101895T2 (hu)
WO (1) WO2000040226A2 (hu)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455564B1 (en) * 1999-01-06 2002-09-24 Pharmacia & Upjohn Company Method of treating sexual disturbances
CN1176086C (zh) * 1999-02-05 2004-11-17 法玛西雅厄普约翰美国公司 制备(5R)-甲氨基-5,6-二氢-4H-咪唑并[4,5,1-ij]喹啉-2(1H)-酮的方法
EP1175204A4 (en) * 1999-05-04 2006-05-31 Aradigm Corp AEROSOL FORMULATION AND ARTICLES FOR INCREASING LIBIDO IN WOMEN BY MOMENTARY TESTOSTERONE ADMINISTRATION
US7258850B2 (en) 1999-05-04 2007-08-21 Aradigm Corporation Methods and compositions for treating erectile dysfunction
CN1189211C (zh) * 1999-06-23 2005-02-16 巴斯德研究所 用于治疗人际关系异常和行为障碍的治疗方法和组合物
CN1554341A (zh) 2000-04-21 2004-12-15 �������Ŷ���Լ��������˾ 用于治疗纤维肌痛和慢性疲劳综合症的化合物
AR033520A1 (es) * 2000-04-27 2003-12-26 Upjohn Co (5r)-(metilamino) -5,6-dihidro-4h-imidazo[4,5,1-ij] quinolin-2(1h)-tiona
AR031152A1 (es) 2000-10-31 2003-09-10 Upjohn Co Tratamientos nuevos para el sindrome de piernas inquietas
IL157320A0 (en) * 2001-02-08 2004-02-19 Pharmacia Corp Rapid-onset medicament for the treatment of sexual dysfunction
US20030073609A1 (en) 2001-06-29 2003-04-17 Pinkerton Thomas C. Enhanced pharmacokinetic profile of intradermally delivered substances
TW200307682A (en) 2002-04-25 2003-12-16 Wyeth Corp 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TWI312781B (en) 2002-04-25 2009-08-01 [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TW200307540A (en) 2002-04-25 2003-12-16 Wyeth Corp [1, 4]Diazocino[7, 8, 1-hi] indole derivatives as antipsychotic and antiobesity agents
SE0202365D0 (sv) * 2002-08-05 2002-08-05 Pharmacia Ab New formulation and use thereof
US7037257B1 (en) * 2002-08-22 2006-05-02 Koenig J Frank Erectile dysfuction treatments comprising momentary vacuum therapy alone or with medications
CA2500922A1 (en) * 2002-10-04 2004-04-22 Pharmacia Corporation Pharmaceutical compositions for treatment of parkinson's disease
EP1545521A2 (en) * 2002-10-04 2005-06-29 Pharmacia Corporation Compositions and methods for treating sexual dysfunction
BRPI0414149A (pt) * 2003-09-05 2006-10-31 Novartis Ag composições compreendendo derivados de benzo(g)-quinolina e derivados de prostaglandina
GT200500317A (es) 2004-11-05 2006-10-27 Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
AR054849A1 (es) 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
JP2009502961A (ja) 2005-07-29 2009-01-29 コンサート ファーマシューティカルズ インコーポレイテッド 新規な医薬組成物
EP1937217A2 (en) * 2005-09-13 2008-07-02 Elan Pharma International Limited Nanoparticulate tadalafil formulations
US7615075B2 (en) * 2005-11-04 2009-11-10 Rush University Medical Center Plastic implant impregnated with a degradation protector
US20080004310A1 (en) * 2006-06-19 2008-01-03 Applied Pharmacy Services, Inc. Lyophilized pharmaceutical composition
WO2017100324A1 (en) * 2015-12-10 2017-06-15 Repros Therapeutics Inc. Combination therapy for treating female hypoactive sexual desire disorders
WO2019055877A1 (en) 2017-09-15 2019-03-21 Forma Therapeutics, Inc. TETRAHYDROIMIDAZO QUINOLINE COMPOSITIONS AS INHIBITORS OF CBP / P300
CN112513038B (zh) 2018-06-29 2023-01-10 福马疗法公司 抑制creb结合蛋白(cbp)
CN113874017A (zh) * 2019-03-15 2021-12-31 福马治疗股份有限公司 抑制环amp-应答元件结合蛋白(creb)
US11795168B2 (en) 2020-09-23 2023-10-24 Forma Therapeutics, Inc. Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP)
US11801243B2 (en) 2020-09-23 2023-10-31 Forma Therapeutics, Inc. Bromodomain inhibitors for androgen receptor-driven cancers
EP4039746A1 (de) 2021-02-08 2022-08-10 Covestro Deutschland AG Polycarbonat-polyester zusammensetzung, formmasse und formkörper mit guter schlagzähigkeit und hoher thermischer belastbarkeit

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4127118B1 (en) 1977-03-16 1995-12-19 Alvaro Latorre Method of effecting and enhancing an erection
US4801587A (en) 1987-03-02 1989-01-31 Gene Voss Impotence ointment
US4935514A (en) * 1989-06-06 1990-06-19 Ethyl Corporation Thiation process
KR0167346B1 (ko) * 1989-06-09 1999-01-15 로버트 에이. 아미테이지 중추신경계 활성을 갖는 헤테로사이클릭 아민
US5273975A (en) * 1989-06-09 1993-12-28 The Upjohn Company Heterocyclic amines having central nervous system activity
US5242391A (en) 1990-04-25 1993-09-07 Alza Corporation Urethral insert for treatment of erectile dysfunction
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
US5541211A (en) 1991-06-18 1996-07-30 Orion-Yhtyma Oy Administration of atipamezole to elicit a yohimbine-like alpha-adrenoreceptor antagonistic noradrenergic transmission
GB9311920D0 (en) 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
EP0724584B1 (en) * 1993-07-27 1997-11-05 PHARMACIA & UPJOHN COMPANY Heterocyclic amines having central nervous system activity
US5565466A (en) * 1993-08-13 1996-10-15 Zonagen, Inc. Methods for modulating the human sexual response
DE69534693T2 (de) 1994-04-22 2006-08-31 Pentech Pharmaceuticals, Inc., Wheeling Sublinguale Zusammensetzung enthaltend Apomorphine zur Diagnose der funktionellen Impotenz
EP0985671B1 (en) * 1996-05-31 2003-04-02 Mochida Pharmaceutical Co., Ltd. PYRIDOCARBAZOLE DERIVATIVES HAVING cGMP-PDE INHIBITORY EFFECT
US6455564B1 (en) * 1999-01-06 2002-09-24 Pharmacia & Upjohn Company Method of treating sexual disturbances

Also Published As

Publication number Publication date
US20040214823A1 (en) 2004-10-28
EA005412B1 (ru) 2005-02-24
US20030004152A1 (en) 2003-01-02
HUP0105036A2 (hu) 2002-05-29
PE20001374A1 (es) 2000-11-19
US20040214826A1 (en) 2004-10-28
CA2350946A1 (en) 2000-07-13
ID30276A (id) 2001-11-15
US6890945B2 (en) 2005-05-10
US6921771B2 (en) 2005-07-26
IL144172A0 (en) 2002-05-23
US20040214824A1 (en) 2004-10-28
HK1041812A1 (zh) 2002-07-26
KR20010089779A (ko) 2001-10-08
US6455564B1 (en) 2002-09-24
US20040214825A1 (en) 2004-10-28
NZ512820A (en) 2002-12-20
CO5150156A1 (es) 2002-04-29
TR200101895T2 (tr) 2001-12-21
US20020107247A1 (en) 2002-08-08
EA200100750A1 (ru) 2001-12-24
CZ20012459A3 (cs) 2002-01-16
US20020198187A1 (en) 2002-12-26
EA200401256A1 (ru) 2005-12-29
AU782596B2 (en) 2005-08-11
WO2000040226A3 (en) 2001-02-01
AU2348200A (en) 2000-07-24
US6809112B2 (en) 2004-10-26
JP2002534376A (ja) 2002-10-15
HUP0105036A3 (en) 2002-10-28
EP1140092A2 (en) 2001-10-10
US20030013710A1 (en) 2003-01-16
BR9916759A (pt) 2001-09-25
US6903127B2 (en) 2005-06-07
CN1332628A (zh) 2002-01-23
WO2000040226A2 (en) 2000-07-13

Similar Documents

Publication Publication Date Title
SK7732001A3 (en) Method of treating sexual disturbances
TWI300351B (en) Pharmaceutical compositions for the treatment of neoplasms
US20090239881A1 (en) Combinations of Flibanserin with Caffeine, Process for Their Preparation and Use Thereof as Medicaments
JP6810613B2 (ja) 有機化合物
JP2002508315A (ja) 性的不能の治療に有効な組合せ
BG107217A (bg) Апоморфинови производни и методи за тяхното използване
ES2270517T3 (es) Terapia de combinacion para modular la respuesta sexual humana.
US9849133B2 (en) Pharmaceutical formulations of xanthine or xanthine derivatives, and their use
US9221825B2 (en) Pyrazolopyrimidinone compound and imidazo triazone compound for treating erectile dysfunction
MXPA01006909A (en) Method of treating sexual disturbances
US20060040929A1 (en) (5R)-(methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline-2(1H)-thione and method of preparation thereof
US20100311785A1 (en) Combination Therapy For Modulating The Human Sexual Response
ZA200104283B (en) Method of treating sexual disturbances.
US8741893B2 (en) 6,7-dihydro-[1,3,4]thiadiazolo-[3,2-a][1,3]diazepin derivatives and pharmaceutical compositions containing the same as hypnotic or anesthetic agent and method for their preparation
US20070219220A1 (en) Pyrazolopyrimidinethione Derivatives, Salts and Solvates Thereof, Preparation Methods and Use Thereof
CN104619323A (zh) 用于在治疗性功能障碍中使用的a3腺苷受体配体
MXPA99010400A (en) Combination therapy for modulating the human sexual response
JPH0149130B2 (hu)